<article article-type="research-article" dtd-version="1.4" xml:lang="en"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">iScience</journal-id><journal-id journal-id-type="iso-abbrev">iScience</journal-id><journal-id journal-id-type="pmc-domain-id">3532</journal-id><journal-id journal-id-type="pmc-domain">isci</journal-id><journal-title-group><journal-title>iScience</journal-title></journal-title-group><issn pub-type="epub">2589-0042</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12855586</article-id><article-id pub-id-type="pmcid-ver">PMC12855586.1</article-id><article-id pub-id-type="pmcaid">12855586</article-id><article-id pub-id-type="pmcaiid">12855586</article-id><article-id pub-id-type="pmid">41623453</article-id><article-id pub-id-type="doi">10.1016/j.isci.2025.114613</article-id><article-id pub-id-type="pii">S2589-0042(25)02874-3</article-id><article-id pub-id-type="publisher-id">114613</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Hepatotoxicity of new-generation ALK inhibitors versus crizotinib in patients with non-small cell lung cancer: A systematic review and meta-analysis</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name name-style="western"><surname>Luo</surname><given-names initials="X">Xingxian</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="fn1">5</xref></contrib><contrib contrib-type="author" id="au2"><name name-style="western"><surname>Du</surname><given-names initials="X">Xin</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="fn1">5</xref></contrib><contrib contrib-type="author" id="au3"><name name-style="western"><surname>Chen</surname><given-names initials="Q">Qi</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author" id="au4"><name name-style="western"><surname>Wang</surname><given-names initials="C">Cen</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author" id="au5"><name name-style="western"><surname>Li</surname><given-names initials="L">Lizong</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author" id="au6"><name name-style="western"><surname>He</surname><given-names initials="X">Xu</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author" id="au7"><name name-style="western"><surname>Gong</surname><given-names initials="Y">Yiru</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author" id="au8"><name name-style="western"><surname>Chen</surname><given-names initials="J">Jiali</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author" id="au9"><name name-style="western"><surname>Zhong</surname><given-names initials="X">Xue</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author" id="au10"><name name-style="western"><surname>Liu</surname><given-names initials="Y">Yi</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author" id="au11"><name name-style="western"><surname>Zhang</surname><given-names initials="X">Xiaohong</given-names></name><email>zhangxiaohong@pkuph.edu.cn</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">∗</xref></contrib><contrib contrib-type="author" id="au12"><name name-style="western"><surname>Huang</surname><given-names initials="L">Lin</given-names></name><email>huanglin@pkuph.edu.cn</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="fn2">6</xref><xref ref-type="corresp" rid="cor2">∗∗</xref></contrib><aff id="aff1"><label>1</label>Department of Pharmacy, Peking University People’s Hospital, Beijing, China</aff><aff id="aff2"><label>2</label>Vanke School of Public Health, Tsinghua University, Beijing, China</aff><aff id="aff3"><label>3</label>School of Pharmaceutical Sciences, Tsinghua University, Beijing, China</aff><aff id="aff4"><label>4</label>Liangzhu Laboratory, Zhejiang University, Hangzhou 310023, China</aff></contrib-group><author-notes><corresp id="cor1"><label>∗</label>Corresponding author <email>zhangxiaohong@pkuph.edu.cn</email></corresp><corresp id="cor2"><label>∗∗</label>Corresponding author <email>huanglin@pkuph.edu.cn</email></corresp><fn id="fn1"><label>5</label><p id="ntpara0010">These authors contributed equally</p></fn><fn id="fn2"><label>6</label><p id="ntpara0015">Lead contact</p></fn></author-notes><pub-date pub-type="collection"><day>20</day><month>2</month><year>2026</year></pub-date><pub-date pub-type="epub"><day>02</day><month>1</month><year>2026</year></pub-date><volume>29</volume><issue>2</issue><issue-id pub-id-type="pmc-issue-id">505597</issue-id><elocation-id>114613</elocation-id><history><date date-type="received"><day>27</day><month>8</month><year>2025</year></date><date date-type="rev-recd"><day>1</day><month>12</month><year>2025</year></date><date date-type="accepted"><day>30</day><month>12</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>01</month><year>2026</year></date></event><event event-type="pmc-live"><date><day>31</day><month>01</month><year>2026</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2026-02-02 15:25:12.997"><day>02</day><month>02</month><year>2026</year></date></event></pub-history><permissions><copyright-statement>© 2025 The Author(s)</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref content-type="ccbylicense" specific-use="textmining" xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="main.pdf" xmlns:xlink="http://www.w3.org/1999/xlink"/><abstract id="abs0010"><title>Summary</title><p>Hepatotoxicity is a known side effect of ALK inhibitors in non-small cell lung cancer. This meta-analysis assessed the hepatotoxicity risk, measured by elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST), for new-generation ALK inhibitors versus crizotinib through eight randomized controlled trials with 2,114 patients. The results suggested that new-generation ALK inhibitors were associated with a significantly reduced risk of all-grade ALT elevation (RR = 0.73, 95% confidence interval [CI] [0.58, 0.92]) and a trend toward reduced risk of grades 3–5 ALT elevation (RR = 0.55, 95% CI [0.29, 1.06]). Alectinib, lorlatinib, and brigatinib are associated with lower risks of hepatotoxicity when compared with crizotinib. New-generation ALK inhibitors improved progression-free survival but not in discontinuation rates. Lorlatinib conferred a greater reduction in any grades AST than second-generation inhibitors compared to crizotinib. Our findings suggest that the selection of the ALK inhibitor should be individualized based on the specific profile of hepatotoxicity and their efficacy.</p></abstract><abstract abstract-type="graphical" id="abs0015"><title>Graphical abstract</title><fig id="undfig1" orientation="portrait" position="anchor"><graphic orientation="portrait" position="float" xlink:href="fx1.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/></fig></abstract><abstract abstract-type="author-highlights" id="abs0020"><title>Highlights</title><p><list id="ulist0010" list-type="simple"><list-item id="u0010"><label>•</label><p id="p0010">Alectinib, lorlatinib, and brigatinib have lower hepatotoxicity risk than crizotinib</p></list-item><list-item id="u0015"><label>•</label><p id="p0015">Envonalkib has higher risk of severe hepatotoxicity elevation than crizotinib</p></list-item><list-item id="u0020"><label>•</label><p id="p0020">Lorlatinib has lower hepatotoxicity risk and better PFS than 2<sup>nd</sup>-generation ALK inhibitors</p></list-item><list-item id="u0025"><label>•</label><p id="p0025">New ALK inhibitors have better PFS than crizotinib, but similar discontinuation rates</p></list-item></list></p></abstract><abstract abstract-type="teaser" id="abs0025"><p>Health sciences; Medicine; Medical specialty; Internal medicine; Oncology</p></abstract><kwd-group id="kwrds0010"><title>Subject areas</title><kwd>Health sciences</kwd><kwd>Medicine</kwd><kwd>Medical specialty</kwd><kwd>Internal medicine</kwd><kwd>Oncology</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta><notes><p id="misc9010">Published: January 2, 2026</p></notes></front><body><sec id="sec1"><title>Introduction</title><p id="p0030">Anaplastic lymphoma kinase (ALK) inhibitors play a central role in the treatment of ALK-positive non-small cell lung cancer (NSCLC), a molecular subtype defined by ALK gene rearrangements.<xref ref-type="bibr" rid="bib1"><sup>1</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib2"><sup>2</sup></xref> Crizotinib, the first-generation ALK tyrosine kinase inhibitor, demonstrated significant clinical activity but was limited by poor central nervous system (CNS) penetration and the rapid emergence of resistance.<xref ref-type="bibr" rid="bib1"><sup>1</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib3"><sup>3</sup></xref> A principal mechanism is ALK-dependent resistance, characterized by the acquisition of secondary mutations within the ALK kinase domain (e.g., G1202R and L1196M), which impair drug binding and restore oncogenic signaling.<xref ref-type="bibr" rid="bib4"><sup>4</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib5"><sup>5</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib6"><sup>6</sup></xref> To address these limitations, several second-generation (2<sup>nd</sup>) ALK inhibitors, such as alectinib,<xref ref-type="bibr" rid="bib7"><sup>7</sup></xref> brigatinib,<xref ref-type="bibr" rid="bib8"><sup>8</sup></xref> ensartinib,<xref ref-type="bibr" rid="bib9"><sup>9</sup></xref> envonalkib,<xref ref-type="bibr" rid="bib10"><sup>10</sup></xref> iruplinalkib,<xref ref-type="bibr" rid="bib9"><sup>9</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib11"><sup>11</sup></xref> and third-generation (3<sup>rd</sup>) ALK inhibitors, such as lorlatinib<xref ref-type="bibr" rid="bib12"><sup>12</sup></xref> have been developed and shown superior efficacy over crizotinib in randomized trials, with improved progression-free survival (PFS) and CNS activity. As of June 30, 2025, a total of eight ALK inhibitors have been approved globally, with six approved by the US Food and Drug Administration and all eight approved by China’s National Medical Products Administration (<xref ref-type="supplementary-material" rid="mmc1">Table S1</xref>).</p><p id="p0035">Like all targeted therapies, ALK inhibitors are associated with a spectrum of adverse events (AEs). Commonly reported toxicities include gastrointestinal disturbances (e.g., nausea, vomiting, and diarrhea), cardiovascular effects (e.g., bradycardia), and pulmonary toxicity (e.g., interstitial lung disease).<xref ref-type="bibr" rid="bib13"><sup>13</sup></xref> Of particular concern is hepatotoxicity, specifically drug-induced liver injury (DILI), which has been frequently reported with tyrosine kinase inhibitors (TKIs), including ALK inhibitors.<xref ref-type="bibr" rid="bib14"><sup>14</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib15"><sup>15</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib16"><sup>16</sup></xref> Crizotinib, the first-generation ALK inhibitor, is well known for its hepatotoxic effects, including elevations in liver transaminases and, in rare cases, severe DILI such as fulminant hepatic failure or even death.<xref ref-type="bibr" rid="bib13"><sup>13</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib17"><sup>17</sup></xref> Clinical study has shown that up to 38% of patients treated with crizotinib experience liver-related AEs of any grade, with approximately 16% being Grade ≥ 3 AEs.<xref ref-type="bibr" rid="bib3"><sup>3</sup></xref> In addition, our preliminary review of published case reports of severe crizotinib-induced liver injury revealed that over 40% (7/16) of the patients experienced fatal outcomes, highlighting the need for increased clinical vigilance regarding hepatotoxicity (<xref ref-type="supplementary-material" rid="mmc1">Table S2</xref>).</p><p id="p0040">Although new-generation ALK inhibitors have demonstrated significantly improved efficacy in treating ALK-positive NSCLC, hepatotoxicity remains a clinical concern. This risk is illustrated by documented serious hepatotoxicity cases involving 2<sup>nd</sup>-generation agents, such as alectinib, brigatinib, and ceritinib (<xref ref-type="supplementary-material" rid="mmc1">Table S2</xref>).<xref ref-type="bibr" rid="bib13"><sup>13</sup></xref> Also, regulatory authorities require routine liver function monitoring for all approved ALK inhibitors, as reflected in their prescribing information (<xref ref-type="supplementary-material" rid="mmc1">Table S1</xref>). However, it remains unclear whether new-generation ALK inhibitors carry a lower, comparable, or even higher risk of hepatotoxicity compared to crizotinib. Therefore, a systematic comparative evaluation using meta-analysis is warranted to clarify the relative hepatotoxic risk among different ALK inhibitors, thereby guiding clinical decision-making and optimizing risk-benefit assessments.</p><p id="p0045">The aim of this study was to evaluate the risk of all-grade and high-grade hepatotoxicity associated with six new-generation ALK inhibitors (2<sup>nd</sup> ALK inhibitors: alectinib, brigatinib, ensartinib, iruplinalkib, envonalkib and 3<sup>rd</sup> ALK inhibitors: lorlatinib) compared with the first-generation ALK inhibitor (crizotinib) in patients with ALK-positive NSCLC. Drug-specific risk estimates were also calculated through stratified analyses by individual ALK inhibitor. To provide a comprehensive assessment of the risk-benefit profile, PFS, response rate (RR), and discontinuation rate due to AEs were also analyzed.</p></sec><sec id="sec2"><title>Results</title><sec id="sec2.1"><title>Search results</title><p id="p0050">A total of 1,575 records were identified through database searches, including Embase (<italic toggle="yes">n</italic> = 915), PubMed (<italic toggle="yes">n</italic> = 379), Cochrane databases (<italic toggle="yes">n</italic> = 275), and <ext-link ext-link-type="uri" id="intref0010" xlink:href="http://ClinicalTrials.gov" xmlns:xlink="http://www.w3.org/1999/xlink">ClinicalTrials.gov</ext-link> (<italic toggle="yes">n</italic> = 6). After removal of 527 duplicate records, 1,048 records underwent title and abstract screening. Of these, 950 were excluded for irrelevance. The full texts of 98 reports were assessed for eligibility, of which 90 were excluded due to having no outcomes of interest. Finally, 8 studies were included in the analysis, comprising trials of alectinib (<italic toggle="yes">n</italic> = 3),<xref ref-type="bibr" rid="bib7"><sup>7</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib18"><sup>18</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib19"><sup>19</sup></xref> lorlatinib (<italic toggle="yes">n</italic> = 1),<xref ref-type="bibr" rid="bib12"><sup>12</sup></xref> brigatinib (<italic toggle="yes">n</italic> = 1),<xref ref-type="bibr" rid="bib8"><sup>8</sup></xref> ensartinib (<italic toggle="yes">n</italic> = 1),<xref ref-type="bibr" rid="bib9"><sup>9</sup></xref> irupinalkib (<italic toggle="yes">n</italic> = 1),<xref ref-type="bibr" rid="bib11"><sup>11</sup></xref> and envonalkib (<italic toggle="yes">n</italic> = 1)<xref ref-type="bibr" rid="bib10"><sup>10</sup></xref> (<xref ref-type="fig" rid="fig1">Figure 1</xref>).<fig id="fig1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Flowchart for studies inclusion</p></caption><graphic orientation="portrait" position="float" xlink:href="gr1.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/></fig></p></sec><sec id="sec2.2"><title>Characteristics of the studies and quality assessment</title><p id="p0055"><xref ref-type="table" rid="tbl1">Table 1</xref> summarizes the characteristics of the included clinical trials and their quality assessment results. In total, 8 RCTs comparing ALK inhibitors with crizotinib in treatment-naive ALK-positive NSCLC were included, comprising five multi-regional clinical trials,<xref ref-type="bibr" rid="bib7"><sup>7</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib8"><sup>8</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib9"><sup>9</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib12"><sup>12</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib19"><sup>19</sup></xref> two conducted exclusively in China,<xref ref-type="bibr" rid="bib11"><sup>11</sup></xref> and one exclusively in Japan.<xref ref-type="bibr" rid="bib10"><sup>10</sup></xref> Trial enrollment ranged from 187 to 303 patients, and crossover between study arms was allowed in 2 studies.<xref ref-type="bibr" rid="bib8"><sup>8</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib18"><sup>18</sup></xref> The primary efficacy endpoint in all trials was PFS. The methodological quality of each study was assessed using the Jadad scale, which evaluates randomization, blinding, and dropout reporting (range, 0–5). Among the 8 trials, 4 studies were rated as high quality with a Jadad score of 5 (CROWN,<xref ref-type="bibr" rid="bib12"><sup>12</sup></xref> ALTA-1L,<xref ref-type="bibr" rid="bib8"><sup>8</sup></xref> INSPIRE,<xref ref-type="bibr" rid="bib11"><sup>11</sup></xref> and the TQ-B3139<xref ref-type="bibr" rid="bib10"><sup>10</sup></xref> trial), owing to the use of appropriate randomization procedures and blinded independent central review of efficacy outcomes. The remaining 4 studies (ALEX,<xref ref-type="bibr" rid="bib7"><sup>7</sup></xref> J-ALEX,<xref ref-type="bibr" rid="bib18"><sup>18</sup></xref> ALESIA,<xref ref-type="bibr" rid="bib19"><sup>19</sup></xref> and eXalt3<xref ref-type="bibr" rid="bib9"><sup>9</sup></xref>) received a score of 3 due to open-label design without blinded assessment. All trials reported patient withdrawals or dropouts. No evidence of publication bias was detected for primary outcomes, as indicated by funnel plots and the Egger test (<xref ref-type="supplementary-material" rid="mmc1">Figure S1</xref>). The results of the sensitivity analysis showed that the pooled estimates for ALT and AST remained stable after the removal of each individual study (data not shown).<table-wrap id="tbl1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Characteristic of studies included in the meta-analysis</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Source</th><th colspan="1" rowspan="1">Trial number</th><th colspan="1" rowspan="1">Trial name</th><th colspan="1" rowspan="1">Treatment group</th><th colspan="1" rowspan="1">Control group</th><th colspan="1" rowspan="1">Trial design</th><th colspan="1" rowspan="1">Primary efficacy endpoints</th><th colspan="1" rowspan="1">Crossover between study groups</th><th colspan="1" rowspan="1">Enrolled patients</th><th colspan="1" rowspan="1">Females, no./males, no.</th><th colspan="1" rowspan="1">Jadad score</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Peters et al.<xref ref-type="bibr" rid="bib7"><sup>7</sup></xref></td><td colspan="1" rowspan="1"><ext-link ext-link-type="ClinicalTrials.gov" id="intref0055" xlink:href="NCT02075840" xmlns:xlink="http://www.w3.org/1999/xlink">NCT02075840</ext-link></td><td colspan="1" rowspan="1">ALEX</td><td colspan="1" rowspan="1">Alectinib,<break/>600 mg BID</td><td colspan="1" rowspan="1">Crizotinib,<break/>250 mg BID</td><td colspan="1" rowspan="1">MRCT</td><td colspan="1" rowspan="1">PFS</td><td colspan="1" rowspan="1">Not allowed</td><td colspan="1" rowspan="1">303</td><td colspan="1" rowspan="1">164/139</td><td colspan="1" rowspan="1">3</td></tr><tr><td colspan="1" rowspan="1">Hida et al.<xref ref-type="bibr" rid="bib18"><sup>18</sup></xref></td><td colspan="1" rowspan="1">JapicCTI-132316</td><td colspan="1" rowspan="1">J-ALEX</td><td colspan="1" rowspan="1">Alectinib,<break/>600 mg BID</td><td colspan="1" rowspan="1">Crizotinib,<break/>250 mg BID</td><td colspan="1" rowspan="1">Only in Japan</td><td colspan="1" rowspan="1">PFS</td><td colspan="1" rowspan="1">Allowed</td><td colspan="1" rowspan="1">207</td><td colspan="1" rowspan="1">82/125</td><td colspan="1" rowspan="1">3</td></tr><tr><td colspan="1" rowspan="1">Zhou et al.<xref ref-type="bibr" rid="bib19"><sup>19</sup></xref></td><td colspan="1" rowspan="1"><ext-link ext-link-type="ClinicalTrials.gov" id="intref0060" xlink:href="NCT02838420" xmlns:xlink="http://www.w3.org/1999/xlink">NCT02838420</ext-link></td><td colspan="1" rowspan="1">ALESIA</td><td colspan="1" rowspan="1">Alectinib,<break/>300 mg BID</td><td colspan="1" rowspan="1">Crizotinib,<break/>250 mg BID</td><td colspan="1" rowspan="1">MRCT</td><td colspan="1" rowspan="1">PFS</td><td colspan="1" rowspan="1">Not allowed</td><td colspan="1" rowspan="1">187</td><td colspan="1" rowspan="1">98/89</td><td colspan="1" rowspan="1">3</td></tr><tr><td colspan="1" rowspan="1">Shaw et al.<xref ref-type="bibr" rid="bib12"><sup>12</sup></xref></td><td colspan="1" rowspan="1"><ext-link ext-link-type="ClinicalTrials.gov" id="intref0065" xlink:href="NCT03052608" xmlns:xlink="http://www.w3.org/1999/xlink">NCT03052608</ext-link></td><td colspan="1" rowspan="1">CROWN</td><td colspan="1" rowspan="1">Lorlatinib,<break/>100 mg QD</td><td colspan="1" rowspan="1">Crizotinib,<break/>250 mg BID</td><td colspan="1" rowspan="1">MRCT</td><td colspan="1" rowspan="1">PFS</td><td colspan="1" rowspan="1">Not allowed</td><td colspan="1" rowspan="1">296</td><td colspan="1" rowspan="1">175/121</td><td colspan="1" rowspan="1">5</td></tr><tr><td colspan="1" rowspan="1">Horn et al.<xref ref-type="bibr" rid="bib9"><sup>9</sup></xref></td><td colspan="1" rowspan="1"><ext-link ext-link-type="ClinicalTrials.gov" id="intref0070" xlink:href="NCT02767804" xmlns:xlink="http://www.w3.org/1999/xlink">NCT02767804</ext-link></td><td colspan="1" rowspan="1">eXalt3</td><td colspan="1" rowspan="1">Ensartinib,<break/>225 mg QD</td><td colspan="1" rowspan="1">Crizotinib,<break/>250 mg BID</td><td colspan="1" rowspan="1">MRCT</td><td colspan="1" rowspan="1">PFS</td><td colspan="1" rowspan="1">Not allowed</td><td colspan="1" rowspan="1">290</td><td colspan="1" rowspan="1">149/161</td><td colspan="1" rowspan="1">3</td></tr><tr><td colspan="1" rowspan="1">Camidge et al.<xref ref-type="bibr" rid="bib8"><sup>8</sup></xref></td><td colspan="1" rowspan="1"><ext-link ext-link-type="ClinicalTrials.gov" id="intref0075" xlink:href="NCT02737501" xmlns:xlink="http://www.w3.org/1999/xlink">NCT02737501</ext-link></td><td colspan="1" rowspan="1">ALTA-1L</td><td colspan="1" rowspan="1">Brigatinib,<break/>180 mg QD</td><td colspan="1" rowspan="1">Crizotinib,<break/>250 mg BID</td><td colspan="1" rowspan="1">MRCT</td><td colspan="1" rowspan="1">PFS</td><td colspan="1" rowspan="1">Allowed</td><td colspan="1" rowspan="1">275</td><td colspan="1" rowspan="1">150/125</td><td colspan="1" rowspan="1">5</td></tr><tr><td colspan="1" rowspan="1">Shi et al.<xref ref-type="bibr" rid="bib11"><sup>11</sup></xref></td><td colspan="1" rowspan="1"><ext-link ext-link-type="ClinicalTrials.gov" id="intref0080" xlink:href="NCT04632758" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04632758</ext-link></td><td colspan="1" rowspan="1">INSPIRE</td><td colspan="1" rowspan="1">Iruplinalkib,<break/>180 mg QD</td><td colspan="1" rowspan="1">Crizotinib,<break/>250 mg BID</td><td colspan="1" rowspan="1">Only in China</td><td colspan="1" rowspan="1">PFS</td><td colspan="1" rowspan="1">Not allowed</td><td colspan="1" rowspan="1">292</td><td colspan="1" rowspan="1">134/158</td><td colspan="1" rowspan="1">5</td></tr><tr><td colspan="1" rowspan="1">Yang et al.<xref ref-type="bibr" rid="bib10"><sup>10</sup></xref></td><td colspan="1" rowspan="1"><ext-link ext-link-type="ClinicalTrials.gov" id="intref0085" xlink:href="NCT04009317" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04009317</ext-link></td><td colspan="1" rowspan="1">TQ-B3139</td><td colspan="1" rowspan="1">Envonalkib,<break/>600 mg BID</td><td colspan="1" rowspan="1">Crizotinib,<break/>250 mg BID</td><td colspan="1" rowspan="1">Only in China</td><td colspan="1" rowspan="1">PFS</td><td colspan="1" rowspan="1">NR</td><td colspan="1" rowspan="1">264</td><td colspan="1" rowspan="1">136/128</td><td colspan="1" rowspan="1">5</td></tr></tbody></table><table-wrap-foot><fn><p>MRCT, multiregional clinical trials; PFS, progression-free survival; NR, not reported; BID, twice a day; QD, once a day.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec2.3"><title>Primary outcomes</title><p id="p0060"><xref ref-type="table" rid="tbl2">Table 2</xref> summarizes the pooled RR results for the primary outcomes, including any-grade and grades 3–5 AEs for ALT and AST elevation.<table-wrap id="tbl2" orientation="portrait" position="float"><label>Table 2</label><caption><p>RR of hepatotoxicity associated with ALK inhibitors in the treatment of ALK-positive NSCLC</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">ALK inhibitors</th><th colspan="1" rowspan="1">RR (95% CI)</th><th colspan="1" rowspan="1">I<xref ref-type="bibr" rid="bib2"><sup>2</sup></xref> statistic, %</th><th colspan="1" rowspan="1"><italic toggle="yes">p</italic> value</th></tr></thead><tbody><tr><td colspan="4" rowspan="1"><bold>Any grades of ALT elevation</bold></td></tr><tr><td colspan="4" rowspan="1"><hr/></td></tr><tr><td colspan="4" rowspan="1">2<sup>nd</sup>-generation ALK inhibitors</td></tr><tr><td colspan="1" rowspan="1"> Alectinib</td><td colspan="1" rowspan="1">0.55 (0.44, 0.70)</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1"><bold>0.011</bold></td></tr><tr><td colspan="1" rowspan="1"> Envonalkib</td><td colspan="1" rowspan="1">1.09 (0.94, 1.27)</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">0.251</td></tr><tr><td colspan="1" rowspan="1"> Brigatinib</td><td colspan="1" rowspan="1">0.68 (0.57, 0.82)</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td></tr><tr><td colspan="1" rowspan="1"> Ensartinib</td><td colspan="1" rowspan="1">1.08 (0.85, 1.39)</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">0.525</td></tr><tr><td colspan="1" rowspan="1"> Iruplinalkib</td><td colspan="1" rowspan="1">0.85 (0.69, 1.05)</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">0.138</td></tr><tr><td colspan="4" rowspan="1">3<sup>rd</sup>-generation ALK inhibitors</td></tr><tr><td colspan="1" rowspan="1"> Lorlatinib</td><td colspan="1" rowspan="1">0.59 (0.48, 0.72)</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td></tr><tr><td colspan="1" rowspan="1"> Overall</td><td colspan="1" rowspan="1">0.73 (0.58, 0.92)</td><td colspan="1" rowspan="1">85</td><td colspan="1" rowspan="1">0.007</td></tr><tr><td colspan="4" rowspan="1"><hr/></td></tr><tr><td colspan="4" rowspan="1"><bold>Grades 3–5 of ALT elevation</bold></td></tr><tr><td colspan="4" rowspan="1"><hr/></td></tr><tr><td colspan="4" rowspan="1">2<sup>nd</sup>-generation ALK inhibitors</td></tr><tr><td colspan="1" rowspan="1"> Alectinib</td><td colspan="1" rowspan="1">0.26 (0.13, 0.51)</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td></tr><tr><td colspan="1" rowspan="1"> Envonalkib</td><td colspan="1" rowspan="1">2.26 (1.07, 4.77)</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">0.033</td></tr><tr><td colspan="1" rowspan="1"> Brigatinib</td><td colspan="1" rowspan="1">0.39 (0.17, 0.91)</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1"><bold>0.029</bold></td></tr><tr><td colspan="1" rowspan="1"> Ensartinib</td><td colspan="1" rowspan="1">0.57 (0.19, 1.65)</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">0.298</td></tr><tr><td colspan="1" rowspan="1"> Iruplinalkib</td><td colspan="1" rowspan="1">1.04 (0.48, 2.24)</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">0.916</td></tr><tr><td colspan="4" rowspan="1">3<sup>rd</sup>-generation ALK inhibitors</td></tr><tr><td colspan="1" rowspan="1"> Lorlatinib</td><td colspan="1" rowspan="1">0.64 (0.18, 2.20)</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">0.475</td></tr><tr><td colspan="1" rowspan="1"> Overall</td><td colspan="1" rowspan="1">0.55 (0.29, 1.06)</td><td colspan="1" rowspan="1">68.2</td><td colspan="1" rowspan="1">0.073</td></tr><tr><td colspan="4" rowspan="1"><hr/></td></tr><tr><td colspan="4" rowspan="1"><bold>Any grades of AST elevation</bold></td></tr><tr><td colspan="4" rowspan="1"><hr/></td></tr><tr><td colspan="4" rowspan="1">2<sup>nd</sup>-generation ALK inhibitors</td></tr><tr><td colspan="1" rowspan="1"> Alectinib</td><td colspan="1" rowspan="1">0.46 (0.29, 0.74)</td><td colspan="1" rowspan="1">31</td><td colspan="1" rowspan="1"><bold>0.001</bold></td></tr><tr><td colspan="1" rowspan="1"> Envonalkib</td><td colspan="1" rowspan="1">1.13 (0.95, 1.34)</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">0.183</td></tr><tr><td colspan="1" rowspan="1"> Brigatinib</td><td colspan="1" rowspan="1">1.03 (0.88, 1.20)</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">0.718</td></tr><tr><td colspan="1" rowspan="1"> Ensartinib</td><td colspan="1" rowspan="1">1.02 (0.76, 1.40)</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">0.892</td></tr><tr><td colspan="1" rowspan="1"> Iruplinalkib</td><td colspan="1" rowspan="1">1.02 (0.84, 1.23)</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">0.851</td></tr><tr><td colspan="4" rowspan="1">3<sup>rd</sup>-generation ALK inhibitors</td></tr><tr><td colspan="1" rowspan="1"> Lorlatinib</td><td colspan="1" rowspan="1">0.64 (0.53, 0.78)</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td></tr><tr><td colspan="1" rowspan="1"> Overall</td><td colspan="1" rowspan="1">0.83 (0.67, 1.04)</td><td colspan="1" rowspan="1">83</td><td colspan="1" rowspan="1">0.112</td></tr><tr><td colspan="4" rowspan="1"><hr/></td></tr><tr><td colspan="4" rowspan="1"><bold>Grades 3–5 of AST elevation</bold></td></tr><tr><td colspan="4" rowspan="1"><hr/></td></tr><tr><td colspan="4" rowspan="1">2<sup>nd</sup>-generation ALK inhibitors</td></tr><tr><td colspan="1" rowspan="1"> Alectinib</td><td colspan="1" rowspan="1">0.44 (0.21, 0.95)</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1"><bold>0.036</bold></td></tr><tr><td colspan="1" rowspan="1"> Envonalkib</td><td colspan="1" rowspan="1">4.40 (1.28, 15.08)</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1"><bold>0.018</bold></td></tr><tr><td colspan="1" rowspan="1"> Brigatinib</td><td colspan="1" rowspan="1">0.86 (0.30, 2.50)</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">0.787</td></tr><tr><td colspan="1" rowspan="1"> Ensartinib</td><td colspan="1" rowspan="1">0.26 (0.03, 2.26)</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">0.219</td></tr><tr><td colspan="1" rowspan="1"> Iruplinalkib</td><td colspan="1" rowspan="1">1.17 (0.47, 2.95)</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">0.736</td></tr><tr><td colspan="4" rowspan="1">3<sup>rd</sup>-generation ALK inhibitors</td></tr><tr><td colspan="1" rowspan="1"> Lorlatinib</td><td colspan="1" rowspan="1">0.31 (0.09, 1.12)</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">0.074</td></tr><tr><td colspan="1" rowspan="1"> Overall</td><td colspan="1" rowspan="1">0.81 (0.41, 1.59)</td><td colspan="1" rowspan="1">51</td><td colspan="1" rowspan="1">0.541</td></tr></tbody></table><table-wrap-foot><fn><p>RR, risk ratio; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALK, anaplastic lymphoma kinase; NSCLC, non-small cell lung cancer; CI, confidence interval. Bold font indicates a <italic toggle="yes">p</italic> value of less than 0.05.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec2.4"><title>ALT elevation</title><p id="p0065">Among patients treated with new-generation ALK inhibitors, the risk of all-grade ALT elevation was significantly lower compared with crizotinib (RR = 0.73, 95% CI [0.58, 0.92], <italic toggle="yes">p</italic> = 0.007, <italic toggle="yes">I</italic><sup>2</sup> = 85.8%; <xref ref-type="fig" rid="fig2">Figure 2</xref>A). Subgroup analysis for 2<sup>nd</sup>-generation ALK inhibitors showed that alectinib (RR = 0.55, 95% CI [0.44, 0.70], <italic toggle="yes">p</italic> &lt; 0.011) and brigatinib (RR = 0.68, 95% CI [0.57, 0.82], <italic toggle="yes">p</italic> &lt; 0.001) were associated with significantly lower incidence of ALT elevation. In contrast, ensartinib (RR = 1.08, 95% CI [0.85, 1.39], <italic toggle="yes">p</italic> = 0.525), iruplinalkib (RR = 0.85, 95% CI [0.69, 1.05], <italic toggle="yes">p</italic> = 0.138), and envonalkib (RR = 1.09, 95% CI [0.94, 1.27], <italic toggle="yes">p</italic> = 0.251) did not show statistically significant differences compared with crizotinib. For 3<sup>rd</sup>-generation ALK inhibitors, lorlatinib significantly reduced the risk of ALT elevation (RR = 0.59, 95% CI [0.48, 0.77], <italic toggle="yes">p</italic> &lt; 0.001) (<xref ref-type="table" rid="tbl2">Table 2</xref>).<fig id="fig2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Pooled RR of all-grade and grades 3–5 alanine aminotransferase elevation of crizotinib versus new ALK inhibitors</p><p>IV, inverse variance method; RR, risk ratio; ALKi, anaplastic lymphoma kinase inhibitors. Data are represented as RR and 95% CI.</p></caption><graphic orientation="portrait" position="float" xlink:href="gr2.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/></fig></p><p id="p0070">For grades 3–5 ALT elevation, the new-generation ALK inhibitors demonstrated a non-significant trend toward reduced risk (RR = 0.55, 95% CI [0.29, 1.06], <italic toggle="yes">p</italic> = 0.073, <italic toggle="yes">I</italic><sup>2</sup> = 68.5%). Subgroup analysis for 2<sup>nd</sup>-generation ALK inhibitors showed that alectinib (RR = 0.26, 95% CI [0.13, 0.51], <italic toggle="yes">p</italic> &lt; 0.001) and brigatinib (RR = 0.39, 95% CI [0.17, 0.91], <italic toggle="yes">p</italic> = 0.029) significantly reduced the risk of grades 3–5 ALT elevation. Conversely, envonalkib was associated with a significantly increased risk (RR = 2.26, 95% CI [1.07, 4.77], <italic toggle="yes">p</italic> = 0.033), whereas ensartinib and iruplinalkib showed no statistically significant difference from crizotinib. For 3<sup>rd</sup>-generation ALK inhibitor, lorlatinib did not significantly reduce the risk of grades 3–5 ALT elevation (RR = 0.64, 95% CI [0.18, 2.20], <italic toggle="yes">p</italic> = 0.475) (<xref ref-type="fig" rid="fig2">Figures 2</xref>B; <xref ref-type="table" rid="tbl2">Table 2</xref>).</p><p id="p0075">Compared to crizotinib, both 2<sup>nd</sup>- and 3<sup>rd</sup>-generation ALK inhibitors are similar to each other in reducing the risk of any grade (<italic toggle="yes">p</italic> = 0.124) and grades 3–5 ALT elevation (<italic toggle="yes">p</italic> = 0.814) (<xref ref-type="fig" rid="fig2">Figures 2</xref>A and 2B).</p></sec><sec id="sec2.5"><title>AST elevation</title><p id="p0080">The risk of all-grade AST elevation with new-generation ALK inhibitors compared with crizotinib was not significant (RR = 0.83, 95% CI [0.67, 1.04], <italic toggle="yes">p</italic> = 0.112, <italic toggle="yes">I</italic><sup>2</sup> = 83.9%). For 2<sup>nd</sup>-generation ALK inhibitors, alectinib showed a significant reduction (RR = 0.46, 95% CI [0.29, 0.74], <italic toggle="yes">p</italic> = 0.001) while brigatinib (RR = 1.03, 95% CI [0.88, 1.20], <italic toggle="yes">p</italic> = 0.718), ensartinib (RR = 1.02, 95% CI [0.76, 1.40], <italic toggle="yes">p</italic> = 0.892), iruplinalkib (RR = 1.02, 95% CI [0.84, 1.23], <italic toggle="yes">p</italic> = 0.851), and envonalkib (RR = 1.13, 95% CI [0.95, 1.34], <italic toggle="yes">p</italic> = 0.183) showed no significant differences compared to crizotinib. For 3<sup>rd</sup>-generation ALK inhibitor, lorlatinib significantly reduced the risk of AST elevation (RR = 0.64, 95% CI [0.53, 0.78], <italic toggle="yes">p</italic> &lt; 0.001) (<xref ref-type="fig" rid="fig3">Figure 3</xref>A; <xref ref-type="table" rid="tbl2">Table 2</xref>).<fig id="fig3" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Pooled RR of all-grade and grades 3–5 aspartate aminotransferase elevation</p><p>IV, inverse variance method; RR, risk ratio; ALKi, anaplastic lymphoma kinase inhibitors. Data are represented as RR and 95% CI.</p></caption><graphic orientation="portrait" position="float" xlink:href="gr3.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/></fig></p><p id="p0085">For grades 3–5 AST elevation, the new-generation ALK inhibitors were not associated with a significant reduction in risk compared to crizotinib (RR = 0.81, 95% CI [0.41, 1.59], <italic toggle="yes">p</italic> = 0.392, <italic toggle="yes">I</italic><sup>2</sup> = 50.8%). Subgroup analysis for 2<sup>nd</sup>-generation ALK inhibitors showed that alectinib (RR = 0.44, 95% CI [0.21, 0.95], <italic toggle="yes">p</italic> = 0.036) and significantly reduced the risk of severe AST elevation. In contrast, envonalkib was associated with a significantly increased risk of grades 3–5 AST elevation (RR, 4.40, 95% CI [1.28, 15.08], <italic toggle="yes">p</italic> = 0.018), whereas brigatinib, ensartinib, and iruplinalkib did not significantly differ from crizotinib. For 3<sup>rd</sup>-generation ALK inhibitor, lorlatinib showed a non-significant benefit (RR = 0.31, 95% CI [0.09, 1.12], <italic toggle="yes">p</italic> = 0.074) (<xref ref-type="fig" rid="fig3">Figure 3</xref>B; <xref ref-type="table" rid="tbl2">Table 2</xref>).</p><p id="p0090">Compared to crizotinib, 3<sup>rd</sup>-generation ALK inhibitors were associated with an even greater reduction in any-grade AST than 2<sup>nd</sup>-generation inhibitors (<italic toggle="yes">p</italic> = 0.017), though no significant difference was observed for grades 3–5 AST (<italic toggle="yes">p</italic> = 0.636) (<xref ref-type="fig" rid="fig3">Figures 3</xref>A and 3B).</p></sec><sec id="sec2.6"><title>Secondary outcomes</title><p id="p0095"><xref ref-type="table" rid="tbl3">Table 3</xref> and <xref ref-type="fig" rid="fig4">Figure 4</xref> presents the pooled results of hazard ratio (HR) for PFS, risk ratio (RR) for objective response rate (ORR), and discontinuation rate for secondary outcomes.<table-wrap id="tbl3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Pooled results of PFS, response rate, and discontinuation rate associated with ALK inhibitors in the treatment of NSCLC</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">ALK inhibitors</th><th colspan="1" rowspan="1">HR/RR (95% CI)</th><th colspan="1" rowspan="1">I<xref ref-type="bibr" rid="bib2"><sup>2</sup></xref> statistic, %</th><th colspan="1" rowspan="1"><italic toggle="yes">p</italic> value</th></tr></thead><tbody><tr><td colspan="4" rowspan="1"><bold>Progression-free survival</bold></td></tr><tr><td colspan="4" rowspan="1"><hr/></td></tr><tr><td colspan="4" rowspan="1">2<sup>nd</sup>-generation ALK inhibitors</td></tr><tr><td colspan="1" rowspan="1"> Alectinib</td><td colspan="1" rowspan="1">0.39 (0.32, 0.47)</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td colspan="1" rowspan="1"> Brigatinib</td><td colspan="1" rowspan="1">0.49 (0.35, 0.66)</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td colspan="1" rowspan="1"> Ensartinib</td><td colspan="1" rowspan="1">0.52 (0.36, 0.73)</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td colspan="1" rowspan="1"> Iruplinalkib</td><td colspan="1" rowspan="1">0.35 (0.24, 0.48)</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td colspan="1" rowspan="1"> Envonalkib</td><td colspan="1" rowspan="1">0.47 (0.34, 0.64)</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td colspan="4" rowspan="1">3<sup>rd</sup>-generation ALK inhibitors</td></tr><tr><td colspan="1" rowspan="1"> Lorlatinib</td><td colspan="1" rowspan="1">0.20 (0.13, 0.27)</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td colspan="1" rowspan="1">Overall</td><td colspan="1" rowspan="1">0.38 (0.31, 0.47)</td><td colspan="1" rowspan="1">68</td><td colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td colspan="4" rowspan="1"><hr/></td></tr><tr><td colspan="4" rowspan="1"><bold>Response rate</bold></td></tr><tr><td colspan="4" rowspan="1"><hr/></td></tr><tr><td colspan="4" rowspan="1">2<sup>nd</sup>-generation ALK inhibitors</td></tr><tr><td colspan="1" rowspan="1"> Alectinib</td><td colspan="1" rowspan="1">1.09 (1.03, 1.15)</td><td colspan="1" rowspan="1">16.8</td><td colspan="1" rowspan="1">0.001</td></tr><tr><td colspan="1" rowspan="1"> Brigatinib</td><td colspan="1" rowspan="1">1.19 (1.02, 1.41)</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">0.032</td></tr><tr><td colspan="1" rowspan="1"> Ensartinib</td><td colspan="1" rowspan="1">1.11 (0.96, 1.29)</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">0.165</td></tr><tr><td colspan="1" rowspan="1"> Iruplinalkib</td><td colspan="1" rowspan="1">1.04 (0.97, 1.12)</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">0.260</td></tr><tr><td colspan="1" rowspan="1"> Envonalkib</td><td colspan="1" rowspan="1">1.16 (1.01, 1.32)</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">0.037</td></tr><tr><td colspan="4" rowspan="1">3<sup>rd</sup>-generation ALK inhibitors</td></tr><tr><td colspan="1" rowspan="1"> Lorlatinib</td><td colspan="1" rowspan="1">1.29 (1.11, 1.49)</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">0.001</td></tr><tr><td colspan="1" rowspan="1">Overall</td><td colspan="1" rowspan="1">1.12 (1.07, 1.17)</td><td colspan="1" rowspan="1">22.3</td><td colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td colspan="4" rowspan="1"><hr/></td></tr><tr><td colspan="4" rowspan="1"><bold>Discontinuation rate</bold></td></tr><tr><td colspan="4" rowspan="1"><hr/></td></tr><tr><td colspan="4" rowspan="1">2<sup>nd</sup>-generation ALK inhibitors</td></tr><tr><td colspan="1" rowspan="1"> Alectinib</td><td colspan="1" rowspan="1">0.69 (0.45, 1.05)</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0.084</td></tr><tr><td colspan="1" rowspan="1"> Envonalkib</td><td colspan="1" rowspan="1">1.62 (0.55, 4.84)</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">0.384</td></tr><tr><td colspan="1" rowspan="1"> Brigatinib</td><td colspan="1" rowspan="1">1.51 (0.76, 3.02)</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">0.242</td></tr><tr><td colspan="1" rowspan="1"> Ensartinib</td><td colspan="1" rowspan="1">1.37 (0.60, 3.15)</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">0.458</td></tr><tr><td colspan="1" rowspan="1"> Iruplinalkib</td><td colspan="1" rowspan="1">1.19 (0.44, 3.20)</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">0.729</td></tr><tr><td colspan="4" rowspan="1">3<sup>rd</sup>-generation ALK inhibitors</td></tr><tr><td colspan="1" rowspan="1"> Lorlatinib</td><td colspan="1" rowspan="1">1.06 (0.53, 2.11)</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">0.875</td></tr><tr><td colspan="1" rowspan="1"> Overall</td><td colspan="1" rowspan="1">1.14 (0.86, 1.51)</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0.370</td></tr></tbody></table><table-wrap-foot><fn><p>ALK, anaplastic lymphoma kinase; PFS, progression-free survival; HR, hazard ratio; RR, risk ratio; ; CI, confidence interval; NA, not available.</p></fn></table-wrap-foot></table-wrap><fig id="fig4" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Pooled analysis of PFS, response rate, and discontinuation rate</p><p>IV, inverse variance method; HR, hazard ratio; RR, risk ratio; ALKi, anaplastic lymphoma kinase inhibitors. Data are represented as HR or RR and 95% CI.</p></caption><graphic orientation="portrait" position="float" xlink:href="gr4.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/></fig></p></sec><sec id="sec2.7"><title>Progression-free survival</title><p id="p0100">In pooled analysis of randomized trials, the new-generation ALK inhibitors were associated with a significantly prolonged PFS compared with crizotinib (HR = 0.38, 95% CI [0.31, 0.47], <italic toggle="yes">p</italic> &lt; 0.001, <italic toggle="yes">I</italic><sup>2</sup> = 68.0%). Subgroup analyses of 2<sup>nd</sup>- and 3<sup>rd</sup>-generation ALK inhibitors demonstrated consistent and significant benefits. Lorlatinib exhibited the greatest reduction in risk of progression or death (HR = 0.19, 95% CI [0.13, 0.27], <italic toggle="yes">p</italic> &lt; 0.001), followed by iruplinalkib (HR = 0.34, 95% CI [0.24, 0.48], <italic toggle="yes">p</italic> &lt; 0.001), alectinib (HR = 0.39, 95% CI [0.32, 0.47], <italic toggle="yes">p</italic> &lt; 0.001), envonalkib (HR = 0.47, 95% CI [ 0.34, 0.64], <italic toggle="yes">p</italic> &lt; 0.001), brigatinib (HR = 0.49, 95% CI [0.35, 0.66], <italic toggle="yes">p</italic> &lt; 0.001), and ensartinib (HR = 0.52, 95% CI [0.36, 0.73], <italic toggle="yes">p</italic> &lt; 0.001). Lorlatinib was associated with a significantly improved PFS compared to 2<sup>nd</sup>-generation ALK inhibitors (<italic toggle="yes">p</italic> &lt; 0.001) (<xref ref-type="fig" rid="fig4">Figure 4</xref>A; <xref ref-type="table" rid="tbl3">Table 3</xref>).</p></sec><sec id="sec2.8"><title>Response rate</title><p id="p0105">In pooled analysis, the new-generation ALK inhibitors were associated with a significantly higher of achieving ORR compared with crizotinib (RR = 1.12, 95% CI [1.07, 1.17], <italic toggle="yes">p</italic> &lt; 0.001, <italic toggle="yes">I</italic><sup>2</sup> = 22.3%). Among individual agents, lorlatinib showed the superior in ORR rate (RR = 1.29, 95% CI [1.11, 1.49], <italic toggle="yes">p</italic> = 0.001), followed by brigatinib (RR = 1.19, 95% CI [1.02, 1.41], <italic toggle="yes">p</italic> = 0.032), alectinib (RR = 1.09, 95% CI [1.03, 1.15], <italic toggle="yes">p</italic> = 0.001), and envonalkib (RR = 1.16, 95% CI [1.01, 1.32], <italic toggle="yes">p</italic> = 0.037). Ensartinib (RR = 1.11, 95% CI [0.96, 1.29], <italic toggle="yes">p</italic> = 0.165) and iruplinalkib (RR = 1.04, 95% CI [0.97, 1.12], <italic toggle="yes">p</italic> = 0.260) did not demonstrate a statistically significant difference in ORR compared to crizotinib. The 2<sup>nd</sup>- and 3<sup>rd</sup>-generation ALK inhibitors showed comparable ORR when compared with the crizotinib (<italic toggle="yes">p</italic> = 0.053) (<xref ref-type="fig" rid="fig4">Figure 4</xref>B; <xref ref-type="table" rid="tbl3">Table 3</xref>).</p></sec><sec id="sec2.9"><title>Discontinuation rate due to AEs</title><p id="p0110">There was no statistically significant difference in the risk of discontinuation rate due to AEs between the new-generation ALK inhibitors and crizotinib (RR = 1.14, 95% CI [0.86, 1.51], <italic toggle="yes">p</italic> = 0.370, <italic toggle="yes">I</italic><sup>2</sup> = 0%). Specifically, among the 2<sup>nd</sup>-generation ALK inhibitors, the RR were 0.69 (95% CI [0.45, 1.05], <italic toggle="yes">p</italic> = 0.084) for alectinib, 1.62 (95% CI [0.55, 4.84], <italic toggle="yes">p</italic> = 0.384) for envonalkib, 1.51 (95% CI [0.76, 3.02], <italic toggle="yes">p</italic> = 0.242) for brigatinib, 1.37 (95% CI [0.60, 3.15], <italic toggle="yes">p</italic> = 0.458) for ensartinib, and 1.19 (95% CI [0.44, 3.20], <italic toggle="yes">p</italic> = 0.729) for iruplinalkib. For the 3<sup>rd</sup>-generation inhibitor lorlatinib, the RR was 1.06 (95% CI [0.53, 2.11], <italic toggle="yes">p</italic> = 0.875) (<xref ref-type="fig" rid="fig4">Figure 4</xref>C; <xref ref-type="table" rid="tbl3">Table 3</xref>).</p></sec></sec><sec id="sec3"><title>Discussion</title><p id="p0115">TKIs are widely used in the treatment of various malignancies and are known to cause hepatotoxicity to varying degrees.<xref ref-type="bibr" rid="bib20"><sup>20</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib21"><sup>21</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib22"><sup>22</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib23"><sup>23</sup></xref> A previous meta-analysis that included 12 studies reported that TKIs were associated with a significantly increased risk of high-grade hepatotoxicity compared with control treatments (OR = 4.35).<xref ref-type="bibr" rid="bib22"><sup>22</sup></xref> Another meta-analysis involving 3,691 patients found that the incidence of hepatotoxicity related to anti-angiogenic targeted agents ranged from 23% to 40%, with 5% being classified as high-grade.<xref ref-type="bibr" rid="bib20"><sup>20</sup></xref> Similarly, treatment with vascular endothelial growth factor receptor (VEGFR) inhibitors was associated with significantly higher risks of elevated ALT (RR = 1.57), AST (RR = 1.57), alkaline phosphatase (RR = 1.20), and bilirubin (RR = 1.55) levels compared with controls.<xref ref-type="bibr" rid="bib21"><sup>21</sup></xref> Notably, a recent meta-analysis comparing first-generation and new-generation BCR-ABL inhibitors showed that new-generation inhibitors were associated with a higher risk of both any-grade ALT elevation (RR, 2.89) and high-grade ALT elevation (RR, 1.59), despite their improved response rates.<xref ref-type="bibr" rid="bib15"><sup>15</sup></xref></p><p id="p0120">Previous study summarized data from two ALK inhibitors in a pooled analysis of 1,908 patients, reporting that ALK TKIs were associated with elevations in ALT and AST of any grade in 25.2% and 26.0% of patients, respectively, and high-grade elevations in 7.0% and 9.9%.<xref ref-type="bibr" rid="bib23"><sup>23</sup></xref> However, at that time, only two ALK inhibitors were approved, and all control groups received chemotherapy, limiting the ability to assess the relative hepatotoxicity of new-generation ALK inhibitors compared to first-generation crizotinib. This meta-analysis aimed to evaluate the risk of hepatotoxicity associated with ALK tyrosine kinase inhibitors in patients with ALK-positive NSCLC, with a direct comparison to crizotinib. The results showed that new-generation ALK inhibitors significantly reduced the risk of ALT elevation, while having no significant effect on AST levels. It is important to note that hepatotoxicity risk varies across different new-generation ALK inhibitors. Compared with crizotinib, alectinib, lorlatinib, and brigatinib were associated with a significantly lower risk of hepatotoxicity, whereas envonalkib was associated with an increased risk. These findings provide important evidence for selecting appropriate ALK inhibitors, particularly in patients who discontinued crizotinib due to hepatotoxicity.</p><p id="p0125">Early identification of risk factors for ALK inhibitor-induced hepatotoxicity is crucial for guiding safe and effective treatment decisions. Several published studies, summarized in <xref ref-type="supplementary-material" rid="mmc1">Table S4</xref>, have investigated factors associated with hepatotoxicity, primarily focusing on crizotinib. Jung et al. reported that crizotinib-induced hepatotoxicity may be associated with preexisting liver disease, hepatitis B virus infection, and concomitant use of H2-receptor antagonists or proton pump inhibitors (PPIs).<xref ref-type="bibr" rid="bib24"><sup>24</sup></xref> Similarly, another study found that sex, liver metastases, and the use of H2 blockers or PPIs were potential risk factors for high-grade hepatoxiciy.<xref ref-type="bibr" rid="bib25"><sup>25</sup></xref> Lin et al. reported that combining crizotinib with immune checkpoint inhibitors significantly increased the risk of hepatotoxicity, suggesting the need for close monitoring when crizotinib is used following immunotherapy.<xref ref-type="bibr" rid="bib26"><sup>26</sup></xref> In addition, genetic susceptibility, such as the STAT1 rs10208033 polymorphism, has also been implicated in crizotinib-related liver injury.<xref ref-type="bibr" rid="bib27"><sup>27</sup></xref> However, all current evidence is based on retrospective observational studies, highlighting the need for high-quality prospective studies to validate these findings.</p><p id="p0130">The mechanisms underlying ALK inhibitors-induced hepatotoxicity was not fully understood but may involve multiple pathways (<xref ref-type="supplementary-material" rid="mmc1">Table S4</xref>). Crizotinib has been shown to cause reactive oxygen species (ROS) accumulation and inhibit the Nrf2 antioxidant pathway, leading to mitochondrial dysfunction,<xref ref-type="bibr" rid="bib28"><sup>28</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib29"><sup>29</sup></xref> pyroptosis via NF-κB/NLRP3,<xref ref-type="bibr" rid="bib30"><sup>30</sup></xref> and ferroptosis through Stat1-mediated Nrf2 suppression.<xref ref-type="bibr" rid="bib31"><sup>31</sup></xref> It also disrupts autophagosome-lysosome fusion and alters cholesterol/sphingolipid metabolism while blocking autophagic squalene epoxidase degradation further exacerbates metabolic disturbance and apoptosis.<xref ref-type="bibr" rid="bib32"><sup>32</sup></xref> Earlier studies also reported non-mitochondrial apoptosis<xref ref-type="bibr" rid="bib32"><sup>32</sup></xref> and ROS-mediated DNA damage independent of ALK targets.<xref ref-type="bibr" rid="bib33"><sup>33</sup></xref> In additional, ensartinib induces liver injury mainly via TXNIP-mediated oxidative stress and mitochondrial dysfunction.<xref ref-type="bibr" rid="bib34"><sup>34</sup></xref> These findings highlight the multifaceted mechanisms of ALK inhibitor-induced liver injury and emphasize the importance of identifying intervention strategies as a key focus for future research.</p><p id="p0135">In recent years, the toxic side effects (including hepatotoxicity) caused by excessively high doses of targeted cancer drugs have attracted widespread attention.<xref ref-type="bibr" rid="bib35"><sup>35</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib36"><sup>36</sup></xref> Traditionally, the dose selection of chemotherapy drugs relied on the maximum tolerated dose (MTD) or maximum administered dose (MAD), due to their steep dose-response curve. However, compared to chemotherapy drugs, targeted anticancer agents exhibit a shallower dose-response curve, suggesting that selecting the MTD may not be optimal.<xref ref-type="bibr" rid="bib37"><sup>37</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib38"><sup>38</sup></xref> Additionally, since targeted therapies are administered over prolonged periods, excessively high doses may significantly impair the patients’ adherence and quality of life.<xref ref-type="bibr" rid="bib39"><sup>39</sup></xref> To address this, the US FDA has established a dose optimization initiative (Project Optimus), encouraging the conduct of dose optimization studies, particularly RCT comparing different doses, before the approval of targeted anticancer drugs.<xref ref-type="bibr" rid="bib40"><sup>40</sup></xref> Among the seven ALK inhibitors included in this study, two were approved at the MTD or MAD, while the rest were approved at doses lower than the MTD or MAD. Furthermore, only one of these agents underwent dose optimization through an RCT (eTable 5).<xref ref-type="bibr" rid="bib41"><sup>41</sup></xref> Collectively, the evidence advocates for dose-optimization studies to improve the hepatic safety profile of ALK inhibitors.</p><sec id="sec3.1"><title>Limitations of the study</title><p id="p0140">Several limitations should be considered when interpreting the findings of this meta-analysis. First, the analysis was based on aggregated study-level data rather than individual patient data, which precluded detailed evaluation of patient-specific risk modifiers, such as baseline liver function status, genetic polymorphisms, or prior hepatic disease. Second, although transaminase elevation was the primary indicator of hepatotoxicity, other relevant hepatic biomarkers and clinical outcomes, such as jaundice, bilirubin elevation, and liver failure events, were not evaluated due to limited data. Third, this study only evaluated efficacy outcomes of ORR and PFS, but did not include OS primarily because OS data from most studies were still immature. Therefore, OS outcomes should be incorporated into future risk-benefit assessments. Lastly, data from real-world settings and non-English publications were not included, which may limit the generalizability of the results to broader clinical populations.</p><p id="p0145">This meta-analysis highlights the variability in hepatotoxicity risk among the new-generation ALK inhibitors. Alectinib, lorlatinib, and brigatinib are associated with lower risks of hepatotoxicity when compared with crizotinib. However, envonalkib shows a significantly increased risk of grades 3–5 ALT and AST elevation compared with crizotinib. These findings suggest that new-generation ALK inhibitors do not uniformly reduce hepatotoxicity. Additionally, the cases of hepatotoxicity induced by ALK inhibitors with fatal outcomes primarily associated with crizotinib, suggest that close monitoring of its use is warranted. The mechanisms underlying ALK inhibitor-induced hepatotoxicity still require further elucidation. However, these findings are constrained by the limited number of studies and small sample sizes. Future large-scale, multi-center RCTs with extended follow-up are required to validate these results.</p></sec></sec><sec id="sec4"><title>Resource availability</title><sec id="sec4.1"><title>Lead contact</title><p id="p0150">Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Lin Huang (<email>huanglin@pkuph.edu.cn</email>).</p></sec><sec id="sec4.2"><title>Materials availability</title><p id="p0155">This study did not generate new unique reagents.</p></sec><sec id="sec4.3" sec-type="data-availability"><title>Data and code availability</title><p id="p0160">
<list id="ulist0015" list-type="simple"><list-item id="u0030"><label>•</label><p id="p0165">This study did not generate any new original datasets that require public deposition. The data that support the findings of this study are available from the corresponding author upon reasonable request.</p></list-item><list-item id="u0035"><label>•</label><p id="p0170">No custom code was generated; all analyses were performed using publicly available software as detailed in the <xref ref-type="sec" rid="sec8.1">key resources table</xref>.</p></list-item><list-item id="u0040"><label>•</label><p id="p0175">No additional unique resources requiring specialized access procedures were generated in this study.</p></list-item></list>
</p></sec></sec><sec id="sec5"><title>Acknowledgments</title><p id="p0180">This work was supported by the <funding-source id="gs1"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source> (ref. <award-id award-type="grant" rid="gs1">72304168</award-id>) and <funding-source id="gs2">Peking University People’s Hospital Development Foundation</funding-source> (<award-id award-type="grant" rid="gs2">RS2024-05</award-id>).</p></sec><sec id="sec6"><title>Author contributions</title><p id="p0185">X.L., X.D., and L.H. conceptualized and designed the study; X.L., X.D., and Q.C. conducted the literature review and performed the statistical analysis; C.W., L.L., X.H., Y.G., and J.C. collected the data; X.L. and X.D. drafted the manuscript; X.Z., Y.L., and L.H. reviewed and edited the manuscript; X.H.Z. and L.H. supervised the project.</p></sec><sec id="sec7" sec-type="COI-statement"><title>Declaration of interests</title><p id="p0190">The authors declare no competing interests.</p></sec><sec id="sec8"><title>STAR★Methods</title><sec id="sec8.1"><title>Key resources table</title><p id="p0195">
<table-wrap id="undtbl1" orientation="portrait" position="float"><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">REAGENT or RESOURCE</th><th colspan="1" rowspan="1">SOURCE</th><th colspan="1" rowspan="1">IDENTIFIER</th></tr></thead><tbody><tr><td colspan="3" rowspan="1"><bold>Deposited data</bold></td></tr><tr><td colspan="3" rowspan="1"><hr/></td></tr><tr><td colspan="1" rowspan="1">Cochrane Library</td><td colspan="1" rowspan="1">Cochrane Library</td><td colspan="1" rowspan="1"><ext-link ext-link-type="uri" id="intref0020" xlink:href="https://www.cochranelibrary.com/" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.cochranelibrary.com/</ext-link></td></tr><tr><td colspan="1" rowspan="1">PubMed</td><td colspan="1" rowspan="1">PubMed</td><td colspan="1" rowspan="1"><ext-link ext-link-type="uri" id="intref0025" xlink:href="https://pubmed.ncbi.nlm.nih.gov/" xmlns:xlink="http://www.w3.org/1999/xlink">https://pubmed.ncbi.nlm.nih.gov/</ext-link></td></tr><tr><td colspan="1" rowspan="1">Embase</td><td colspan="1" rowspan="1">Embase</td><td colspan="1" rowspan="1"><ext-link ext-link-type="uri" id="intref0030" xlink:href="https://www.embase.com/" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.embase.com/</ext-link></td></tr><tr><td colspan="1" rowspan="1">ClinicalTrials.gov</td><td colspan="1" rowspan="1">ClinicalTrials.gov</td><td colspan="1" rowspan="1"><ext-link ext-link-type="uri" id="intref0035" xlink:href="https://www.clinicaltrials.gov/" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.clinicaltrials.gov/</ext-link></td></tr></tbody></table></table-wrap>
</p></sec><sec id="sec8.2"><title>Experimental model and study participant details</title><p id="p0200">The study did not use experimental models typical in the life sciences.</p></sec><sec id="sec8.3"><title>Method details</title><sec id="sec8.3.1"><title>Definition of the outcomes</title><p id="p0205">Hepatotoxicity served as the primary outcomes, with comprehensive assessment through serial monitoring of serum hepatic transaminase levels. Specifically, we analyzed both all-grade elevations and clinically significant Grade ≥3 elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST), as defined by the Common Terminology Criteria for Adverse Events (CTCAE) guidelines. For this analysis, the term “new-generation ALK inhibitors” encompassed both 2<sup>nd</sup>-generation agents (alectinib, brigatinib, ensartinib, iruplinalkib and envonalkib) and 3<sup>rd</sup>-generation agents (lorlatinib). The hepatotoxicity of new-generation ALK inhibitors was systematically compared with that of crizotinib. Additionally, data on ORR, PFS and discontinuation rate of ALK inhibitors therapy due to adverse events were taken as the secondary outcomes.</p></sec><sec id="sec8.3.2"><title>Search strategy and study selection</title><p id="p0210">A comprehensive search was conducted across PubMed, Embase, Cochrane Library and <ext-link ext-link-type="uri" id="intref0040" xlink:href="http://ClinicalTrials.gov" xmlns:xlink="http://www.w3.org/1999/xlink">ClinicalTrials.gov</ext-link> from the inception to June 1, 2025. The search strategy incorporated specific keywords and MeSH terms related to “ALK inhibitors” and “non-small cell lung cancer” (NSCLC), with full search syntax and results for each database provided in supplement (<xref ref-type="supplementary-material" rid="mmc1">Appendix S1</xref>; <xref ref-type="supplementary-material" rid="mmc1">Table S3</xref>). Only English-language publications considered (<xref ref-type="supplementary-material" rid="mmc1">Appendix S2</xref>; <xref ref-type="supplementary-material" rid="mmc1">Table S3</xref> in the supplement). The search was supplemented by reviewing completed trials listed on <ext-link ext-link-type="uri" id="intref0045" xlink:href="http://ClinicalTrials.gov" xmlns:xlink="http://www.w3.org/1999/xlink">ClinicalTrials.gov</ext-link> up to June 2025. This study followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines.<xref ref-type="bibr" rid="bib42"><sup>42</sup></xref> The predefined inclusion and exclusion criteria were registered in the International Prospective Register of Systematic Reviews (PROSPERO: CRD420251079727). In cases where trials had multiple publications, we selected only the most recent and comprehensive report for inclusion. Study quality was assessed using the Jadad score.<xref ref-type="bibr" rid="bib43"><sup>43</sup></xref> This systematic review, utilizing only publicly available published data, did not require IRB approval or patient consent (<xref ref-type="fig" rid="fig1">Figure 1</xref>).</p></sec><sec id="sec8.3.3"><title>Data extraction</title><p id="p0215">Two investigators independently conducted data extraction with consensus resolution of discrepancies. The extraction process captured detailed study characteristics including authorship, publication year, trial designs, sample demographics, regimens, dosing schedules, administration frequencies, ALT levels, AST levels, RR, PFS and discontinuation rate related to the AEs. For any missing data in the published literature, we referred to the most up-to-date official drug prescribing information (package insert) as a supplementary source.</p></sec></sec><sec id="sec8.4"><title>Quantification and statistical analysis</title><p id="p0220">Risk ratio (RR) and hazard ratio (HR) with corresponding 95% confidence intervals (CIs) were calculated using the inverse variance method. For studies where the outcomes were not reported with a 95% confidence interval (95% CI), we converted the estimates to 95% CI for consistency (<xref ref-type="supplementary-material" rid="mmc1">Appendix S3</xref> in the supplement). Heterogeneity among studies was assessed using the Q statistic and <italic toggle="yes">I</italic><sup><italic toggle="yes">2</italic></sup> statistic. When significant heterogeneity was detected (<italic toggle="yes">p</italic> &lt; 0.10 for the Q-test or <italic toggle="yes">I</italic><sup><italic toggle="yes">2</italic></sup> &gt; 50%), a random-effects model was employed; otherwise, a fixed-effects model was used. Publication bias was evaluated through funnel plots and Egger’s regression test. Furthermore, we conducted a pooled analysis for each ALK inhibitor separately. Sensitivity analysis was performed by sequentially removing each individual study to evaluate the stability of the overall results. A two-sided <italic toggle="yes">p</italic>-value &lt;0.05 was considered statistically significant. All statistical analyses were conducted using R, version 4.1.0 (R Project for Statistical Computing) with the meta and metafor packages. All analyses were performed between June 2025 and July 2025.</p></sec></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation id="sref1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schneider</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>A.T.</given-names></name></person-group><article-title>ALK-positive lung cancer: a moving target</article-title><source>Nat. Cancer</source><volume>4</volume><year>2023</year><fpage>330</fpage><lpage>343</lpage><pub-id pub-id-type="doi">10.1038/s43018-023-00515-0</pub-id><pub-id pub-id-type="pmid">36797503</pub-id><pub-id pub-id-type="pmcid">PMC10754274</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation id="sref2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reshetnyak</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Rossi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Myasnikov</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Sowaileh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mohanty</surname><given-names>J.</given-names></name><name name-style="western"><surname>Nourse</surname><given-names>A.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Lax</surname><given-names>I.</given-names></name><name name-style="western"><surname>Schlessinger</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kalodimos</surname><given-names>C.G.</given-names></name></person-group><article-title>Mechanism for the activation of the anaplastic lymphoma kinase receptor</article-title><source>Nature</source><volume>600</volume><year>2021</year><fpage>153</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-04140-8</pub-id><pub-id pub-id-type="pmid">34819673</pub-id><pub-id pub-id-type="pmcid">PMC8639797</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation id="sref3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shaw</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Nakagawa</surname><given-names>K.</given-names></name><name name-style="western"><surname>Seto</surname><given-names>T.</given-names></name><name name-style="western"><surname>Crinó</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>De Pas</surname><given-names>T.</given-names></name><name name-style="western"><surname>Besse</surname><given-names>B.</given-names></name><name name-style="western"><surname>Solomon</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Blackhall</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Crizotinib versus chemotherapy in advanced ALK-positive lung cancer</article-title><source>N. Engl. J. Med.</source><volume>368</volume><year>2013</year><fpage>2385</fpage><lpage>2394</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1214886</pub-id><pub-id pub-id-type="pmid">23724913</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation id="sref4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Voena</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ambrogio</surname><given-names>C.</given-names></name><name name-style="western"><surname>Iannelli</surname><given-names>F.</given-names></name><name name-style="western"><surname>Chiarle</surname><given-names>R.</given-names></name></person-group><article-title>ALK in cancer: from function to therapeutic targeting</article-title><source>Nat. Rev. Cancer</source><volume>25</volume><year>2025</year><fpage>359</fpage><lpage>378</lpage><pub-id pub-id-type="doi">10.1038/s41568-025-00797-9</pub-id><pub-id pub-id-type="pmid">40055571</pub-id><pub-id pub-id-type="pmcid">PMC12208075</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation id="sref5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zapata Dongo</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Poterico</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Fontana</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mologni</surname><given-names>L.</given-names></name><name name-style="western"><surname>Alvarez-Chacon</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rojas-Armas</surname><given-names>J.</given-names></name><name name-style="western"><surname>Calla</surname><given-names>J.</given-names></name></person-group><article-title>An in silico evaluation of lorlatinib as a potential therapy for novel amino acid substitutions in the tyrosine kinase domain of the ALK protein associated with cancer</article-title><source>Front. Pharmacol.</source><volume>16</volume><year>2025</year><object-id pub-id-type="publisher-id">1605314</object-id><pub-id pub-id-type="doi">10.3389/fphar.2025.1605314</pub-id><pub-id pub-id-type="pmcid">PMC12213726</pub-id><pub-id pub-id-type="pmid">40606598</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation id="sref6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shreenivas</surname><given-names>A.</given-names></name><name name-style="western"><surname>Janku</surname><given-names>F.</given-names></name><name name-style="western"><surname>Gouda</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.Z.</given-names></name><name name-style="western"><surname>George</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kato</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kurzrock</surname><given-names>R.</given-names></name></person-group><article-title>ALK fusions in the pan-cancer setting: another tumor-agnostic target?</article-title><source>npj Precis. Oncol.</source><volume>7</volume><year>2023</year><fpage>101</fpage><pub-id pub-id-type="doi">10.1038/s41698-023-00449-x</pub-id><pub-id pub-id-type="pmid">37773318</pub-id><pub-id pub-id-type="pmcid">PMC10542332</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation id="sref7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peters</surname><given-names>S.</given-names></name><name name-style="western"><surname>Camidge</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Gadgeel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Ou</surname><given-names>S.H.I.</given-names></name><name name-style="western"><surname>Pérol</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dziadziuszko</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rosell</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer</article-title><source>N. Engl. J. Med.</source><volume>377</volume><year>2017</year><fpage>829</fpage><lpage>838</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1704795</pub-id><pub-id pub-id-type="pmid">28586279</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation id="sref8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Camidge</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.R.</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.C.H.</given-names></name><name name-style="western"><surname>Han</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Hochmair</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Delmonte</surname><given-names>A.</given-names></name><name name-style="western"><surname>Garcia Campelo</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D.W.</given-names></name><etal/></person-group><article-title>Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial</article-title><source>J. Thorac. Oncol.</source><volume>16</volume><year>2021</year><fpage>2091</fpage><lpage>2108</lpage><pub-id pub-id-type="doi">10.1016/j.jtho.2021.07.035</pub-id><pub-id pub-id-type="pmid">34537440</pub-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation id="sref9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Horn</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Poddubskaya</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mok</surname><given-names>T.</given-names></name><name name-style="western"><surname>Reck</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wakelee</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chiappori</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Breder</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial</article-title><source>JAMA Oncol.</source><volume>7</volume><year>2021</year><fpage>1617</fpage><lpage>1625</lpage><pub-id pub-id-type="doi">10.1001/jamaoncol.2021.3523</pub-id><pub-id pub-id-type="pmid">34473194</pub-id><pub-id pub-id-type="pmcid">PMC8414368</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation id="sref10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Min</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Envonalkib versus crizotinib for treatment-naive ALK-positive non-small cell lung cancer: a randomized, multicenter, open-label, phase III trial</article-title><source>Signal Transduct. Targeted Ther.</source><volume>8</volume><year>2023</year><fpage>301</fpage><pub-id pub-id-type="doi">10.1038/s41392-023-01538-w</pub-id><pub-id pub-id-type="pmcid">PMC10423717</pub-id><pub-id pub-id-type="pmid">37574511</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation id="sref11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Iruplinalkib (WX-0593) Versus Crizotinib in ALK TKI-Naive Locally Advanced or Metastatic ALK-Positive NSCLC: Interim Analysis of a Randomized, Open-Label, Phase 3 Study (INSPIRE)</article-title><source>J. Thorac. Oncol.</source><volume>19</volume><year>2024</year><fpage>912</fpage><lpage>927</lpage><pub-id pub-id-type="doi">10.1016/j.jtho.2024.01.013</pub-id><pub-id pub-id-type="pmid">38280448</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation id="sref12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shaw</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Bauer</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>de Marinis</surname><given-names>F.</given-names></name><name name-style="western"><surname>Felip</surname><given-names>E.</given-names></name><name name-style="western"><surname>Goto</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mazieres</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Mok</surname><given-names>T.</given-names></name><name name-style="western"><surname>Polli</surname><given-names>A.</given-names></name><etal/></person-group><article-title>First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer</article-title><source>N. Engl. J. Med.</source><volume>383</volume><year>2020</year><fpage>2018</fpage><lpage>2029</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2027187</pub-id><pub-id pub-id-type="pmid">33207094</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation id="sref13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kassem</surname><given-names>L.</given-names></name><name name-style="western"><surname>Shohdy</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Lasheen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Abdel-Rahman</surname><given-names>O.</given-names></name><name name-style="western"><surname>Ali</surname><given-names>A.</given-names></name><name name-style="western"><surname>Abdel-Malek</surname><given-names>R.R.</given-names></name></person-group><article-title>Safety issues with the ALK inhibitors in the treatment of NSCLC: A systematic review</article-title><source>Crit. Rev. Oncol. Hematol.</source><volume>134</volume><year>2019</year><fpage>56</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1016/j.critrevonc.2018.11.004</pub-id><pub-id pub-id-type="pmid">30771874</pub-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation id="sref14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shah</surname><given-names>R.R.</given-names></name><name name-style="western"><surname>Morganroth</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shah</surname><given-names>D.R.</given-names></name></person-group><article-title>Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives</article-title><source>Drug Saf.</source><volume>36</volume><year>2013</year><fpage>491</fpage><lpage>503</lpage><pub-id pub-id-type="doi">10.1007/s40264-013-0048-4</pub-id><pub-id pub-id-type="pmid">23620168</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation id="sref15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name></person-group><article-title>Comparison of Hepatotoxicity Associated With New BCR-ABL Tyrosine Kinase Inhibitors vs Imatinib Among Patients With Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis</article-title><source>JAMA Netw. Open</source><volume>4</volume><year>2021</year><object-id pub-id-type="publisher-id">e2120165</object-id><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2021.20165</pub-id><pub-id pub-id-type="pmcid">PMC8299317</pub-id><pub-id pub-id-type="pmid">34292334</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation id="sref16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shyam Sunder</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>U.C.</given-names></name><name name-style="western"><surname>Pokharel</surname><given-names>S.</given-names></name></person-group><article-title>Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management</article-title><source>Signal Transduct. Targeted Ther.</source><volume>8</volume><year>2023</year><fpage>262</fpage><pub-id pub-id-type="doi">10.1038/s41392-023-01469-6</pub-id><pub-id pub-id-type="pmcid">PMC10326056</pub-id><pub-id pub-id-type="pmid">37414756</pub-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation id="sref17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kreitman</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nair</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Kothadia</surname><given-names>J.P.</given-names></name></person-group><article-title>Successful Treatment of Crizotinib-Induced Fulminant Liver Failure: A Case Report and Review of Literature</article-title><source>Case Reports Hepatol.</source><volume>2020</volume><year>2020</year><object-id pub-id-type="publisher-id">8247960</object-id><pub-id pub-id-type="doi">10.1155/2020/8247960</pub-id><pub-id pub-id-type="pmcid">PMC7085870</pub-id><pub-id pub-id-type="pmid">32231818</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation id="sref18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hida</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nokihara</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kondo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Azuma</surname><given-names>K.</given-names></name><name name-style="western"><surname>Seto</surname><given-names>T.</given-names></name><name name-style="western"><surname>Takiguchi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Nishio</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yoshioka</surname><given-names>H.</given-names></name><name name-style="western"><surname>Imamura</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial</article-title><source>Lancet (London, England)</source><volume>390</volume><year>2017</year><fpage>29</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1016/s0140-6736(17)30565-2</pub-id><pub-id pub-id-type="pmid">28501140</pub-id></element-citation></ref><ref id="bib19"><label>19</label><element-citation id="sref19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.W.</given-names></name><name name-style="western"><surname>Reungwetwattana</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>He</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Bu</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study</article-title><source>Lancet Respir. Med.</source><volume>7</volume><year>2019</year><fpage>437</fpage><lpage>446</lpage><pub-id pub-id-type="doi">10.1016/s2213-2600(19)30053-0</pub-id><pub-id pub-id-type="pmid">30981696</pub-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation id="sref20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iacovelli</surname><given-names>R.</given-names></name><name name-style="western"><surname>Palazzo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Procopio</surname><given-names>G.</given-names></name><name name-style="western"><surname>Santoni</surname><given-names>M.</given-names></name><name name-style="western"><surname>Trenta</surname><given-names>P.</given-names></name><name name-style="western"><surname>De Benedetto</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mezi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cortesi</surname><given-names>E.</given-names></name></person-group><article-title>Incidence and relative risk of hepatic toxicity in patients treated with anti-angiogenic tyrosine kinase inhibitors for malignancy</article-title><source>Br. J. Clin. Pharmacol.</source><volume>77</volume><year>2014</year><fpage>929</fpage><lpage>938</lpage><pub-id pub-id-type="doi">10.1111/bcp.12231</pub-id><pub-id pub-id-type="pmid">23981115</pub-id><pub-id pub-id-type="pmcid">PMC4093918</pub-id></element-citation></ref><ref id="bib21"><label>21</label><element-citation id="sref21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghatalia</surname><given-names>P.</given-names></name><name name-style="western"><surname>Je</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Mouallem</surname><given-names>N.E.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>P.L.</given-names></name><name name-style="western"><surname>Trinh</surname><given-names>Q.D.</given-names></name><name name-style="western"><surname>Sonpavde</surname><given-names>G.</given-names></name><name name-style="western"><surname>Choueiri</surname><given-names>T.K.</given-names></name></person-group><article-title>Hepatotoxicity with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A meta-analysis of randomized clinical trials</article-title><source>Crit. Rev. Oncol. Hematol.</source><volume>93</volume><year>2015</year><fpage>257</fpage><lpage>276</lpage><pub-id pub-id-type="doi">10.1016/j.critrevonc.2014.11.006</pub-id><pub-id pub-id-type="pmid">25523486</pub-id></element-citation></ref><ref id="bib22"><label>22</label><element-citation id="sref22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Teo</surname><given-names>Y.L.</given-names></name><name name-style="western"><surname>Ho</surname><given-names>H.K.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>A.</given-names></name></person-group><article-title>Risk of tyrosine kinase inhibitors-induced hepatotoxicity in cancer patients: a meta-analysis</article-title><source>Cancer Treat Rev.</source><volume>39</volume><year>2013</year><fpage>199</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.1016/j.ctrv.2012.09.004</pub-id><pub-id pub-id-type="pmid">23099278</pub-id></element-citation></ref><ref id="bib23"><label>23</label><element-citation id="sref23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name></person-group><article-title>Incidence and risk of hepatic toxicities associated with anaplastic lymphoma kinase inhibitors in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis</article-title><source>Oncotarget</source><volume>9</volume><year>2018</year><fpage>9480</fpage><lpage>9488</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.23840</pub-id><pub-id pub-id-type="pmid">29507704</pub-id><pub-id pub-id-type="pmcid">PMC5823621</pub-id></element-citation></ref><ref id="bib24"><label>24</label><element-citation id="sref24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jung</surname><given-names>D.</given-names></name><name name-style="western"><surname>Han</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Yee</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Gwak</surname><given-names>H.S.</given-names></name></person-group><article-title>Factors affecting crizotinib-induced hepatotoxicity in non-small cell lung cancer patients</article-title><source>Med. Oncol.</source><volume>35</volume><year>2018</year><fpage>154</fpage><pub-id pub-id-type="doi">10.1007/s12032-018-1213-5</pub-id><pub-id pub-id-type="pmid">30367285</pub-id></element-citation></ref><ref id="bib25"><label>25</label><element-citation id="sref25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Han</surname><given-names>H.W.</given-names></name><name name-style="western"><surname>Yee</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Moon</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jung</surname><given-names>D.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>Y.S.</given-names></name><name name-style="western"><surname>Seo</surname><given-names>I.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Gwak</surname><given-names>H.S.</given-names></name></person-group><article-title>Factors affecting high-grade hepatotoxicity of tyrosine kinase inhibitors in cancer patients: a multi-center observational study</article-title><source>Eur. J. Clin. Pharmacol.</source><volume>76</volume><year>2020</year><fpage>1183</fpage><lpage>1191</lpage><pub-id pub-id-type="doi">10.1007/s00228-020-02897-x</pub-id><pub-id pub-id-type="pmid">32444938</pub-id></element-citation></ref><ref id="bib26"><label>26</label><element-citation id="sref26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Chin</surname><given-names>E.</given-names></name><name name-style="western"><surname>Yeap</surname><given-names>B.Y.</given-names></name><name name-style="western"><surname>Ferris</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Kamesan</surname><given-names>V.</given-names></name><name name-style="western"><surname>Lennes</surname><given-names>I.T.</given-names></name><name name-style="western"><surname>Sequist</surname><given-names>L.V.</given-names></name><name name-style="western"><surname>Heist</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Mino-Kenudson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gainor</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>A.T.</given-names></name></person-group><article-title>Increased Hepatotoxicity Associated with Sequential Immune Checkpoint Inhibitor and Crizotinib Therapy in Patients with Non-Small Cell Lung Cancer</article-title><source>J. Thorac. Oncol.</source><volume>14</volume><year>2019</year><fpage>135</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1016/j.jtho.2018.09.001</pub-id><pub-id pub-id-type="pmid">30205166</pub-id><pub-id pub-id-type="pmcid">PMC6309637</pub-id></element-citation></ref><ref id="bib27"><label>27</label><element-citation id="sref27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhuang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name></person-group><article-title>Impact of STAT1 polymorphisms on crizotinib-induced hepatotoxicity in ALK-positive non-small cell lung cancer patients</article-title><source>J. Cancer Res. Clin. Oncol.</source><volume>147</volume><year>2021</year><fpage>725</fpage><lpage>737</lpage><pub-id pub-id-type="doi">10.1007/s00432-020-03476-4</pub-id><pub-id pub-id-type="pmid">33387041</pub-id><pub-id pub-id-type="pmcid">PMC11801888</pub-id></element-citation></ref><ref id="bib28"><label>28</label><element-citation id="sref28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>M.</given-names></name></person-group><article-title>An Insight on the Pathways Involved in Crizotinib and Sunitinib Induced Hepatotoxicity in HepG2 Cells and Animal Model</article-title><source>Front. Oncol.</source><volume>12</volume><year>2022</year><object-id pub-id-type="publisher-id">749954</object-id><pub-id pub-id-type="doi">10.3389/fonc.2022.749954</pub-id><pub-id pub-id-type="pmcid">PMC8832280</pub-id><pub-id pub-id-type="pmid">35155225</pub-id></element-citation></ref><ref id="bib29"><label>29</label><element-citation id="sref29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>B.K.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.Y.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>M.</given-names></name></person-group><article-title>Crizotinib and Sunitinib Induce Hepatotoxicity and Mitochondrial Apoptosis in L02 Cells via ROS and Nrf2 Signaling Pathway</article-title><source>Front. Pharmacol.</source><volume>12</volume><year>2021</year><object-id pub-id-type="publisher-id">620934</object-id><pub-id pub-id-type="doi">10.3389/fphar.2021.620934</pub-id><pub-id pub-id-type="pmcid">PMC7883288</pub-id><pub-id pub-id-type="pmid">33597889</pub-id></element-citation></ref><ref id="bib30"><label>30</label><element-citation id="sref30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Lan</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ying</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Z.</given-names></name></person-group><article-title>MgIG exerts therapeutic effects on crizotinib-induced hepatotoxicity by limiting ROS-mediated autophagy and pyroptosis</article-title><source>J. Cell Mol. Med.</source><volume>26</volume><year>2022</year><fpage>4492</fpage><lpage>4505</lpage><pub-id pub-id-type="doi">10.1111/jcmm.17474</pub-id><pub-id pub-id-type="pmid">35855570</pub-id><pub-id pub-id-type="pmcid">PMC9357634</pub-id></element-citation></ref><ref id="bib31"><label>31</label><element-citation id="sref31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>N.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xi</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>The involvement of the Stat1/Nrf2 pathway in exacerbating Crizotinib-induced liver injury: implications for ferroptosis</article-title><source>Cell Death Dis.</source><volume>15</volume><year>2024</year><fpage>600</fpage><pub-id pub-id-type="doi">10.1038/s41419-024-06993-z</pub-id><pub-id pub-id-type="pmid">39160159</pub-id><pub-id pub-id-type="pmcid">PMC11333746</pub-id></element-citation></ref><ref id="bib32"><label>32</label><element-citation id="sref32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Mu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Disturbing Cholesterol/Sphingolipid Metabolism by Squalene Epoxidase Arises Crizotinib Hepatotoxicity</article-title><source>Adv. Sci.</source><volume>12</volume><year>2025</year><object-id pub-id-type="publisher-id">e2414923</object-id><pub-id pub-id-type="doi">10.1002/advs.202414923</pub-id><pub-id pub-id-type="pmcid">PMC11984922</pub-id><pub-id pub-id-type="pmid">39836491</pub-id></element-citation></ref><ref id="bib33"><label>33</label><element-citation id="sref33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Du</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>B.</given-names></name><name name-style="western"><surname>He</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>P.</given-names></name></person-group><article-title>ROS-dependent DNA damage contributes to crizotinib-induced hepatotoxicity via the apoptotic pathway</article-title><source>Toxicol. Appl. Pharmacol.</source><volume>383</volume><year>2019</year><object-id pub-id-type="publisher-id">114768</object-id><pub-id pub-id-type="doi">10.1016/j.taap.2019.114768</pub-id><pub-id pub-id-type="pmid">31639374</pub-id></element-citation></ref><ref id="bib34"><label>34</label><element-citation id="sref34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Du</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Rutin attenuates ensartinib-induced hepatotoxicity by non-transcriptional regulation of TXNIP</article-title><source>Cell Biol. Toxicol.</source><volume>40</volume><year>2024</year><fpage>38</fpage><pub-id pub-id-type="doi">10.1007/s10565-024-09883-4</pub-id><pub-id pub-id-type="pmid">38789868</pub-id><pub-id pub-id-type="pmcid">PMC11126486</pub-id></element-citation></ref><ref id="bib35"><label>35</label><element-citation id="sref35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fourie Zirkelbach</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shah</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vallejo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ayyoub</surname><given-names>A.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hudson</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sridhara</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ison</surname><given-names>G.</given-names></name><name name-style="western"><surname>Amiri-Kordestani</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Improving Dose-Optimization Processes Used in Oncology Drug Development to Minimize Toxicity and Maximize Benefit to Patients</article-title><source>J. Clin. Oncol.</source><volume>40</volume><year>2022</year><fpage>3489</fpage><lpage>3500</lpage><pub-id pub-id-type="doi">10.1200/jco.22.00371</pub-id><pub-id pub-id-type="pmid">36095296</pub-id></element-citation></ref><ref id="bib36"><label>36</label><element-citation id="sref36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shah</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rahman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Theoret</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Pazdur</surname><given-names>R.</given-names></name></person-group><article-title>The Drug-Dosing Conundrum in Oncology - When Less Is More</article-title><source>N. Engl. J. Med.</source><volume>385</volume><year>2021</year><fpage>1445</fpage><lpage>1447</lpage><pub-id pub-id-type="doi">10.1056/NEJMp2109826</pub-id><pub-id pub-id-type="pmid">34623789</pub-id></element-citation></ref><ref id="bib37"><label>37</label><element-citation id="sref37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takimoto</surname><given-names>C.H.</given-names></name></person-group><article-title>Maximum tolerated dose: clinical endpoint for a bygone era?</article-title><source>Target. Oncol.</source><volume>4</volume><year>2009</year><fpage>143</fpage><lpage>147</lpage><pub-id pub-id-type="doi">10.1007/s11523-009-0108-y</pub-id><pub-id pub-id-type="pmid">19377851</pub-id></element-citation></ref><ref id="bib38"><label>38</label><element-citation id="sref38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sachs</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Mayawala</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gadamsetty</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>de Alwis</surname><given-names>D.P.</given-names></name></person-group><article-title>Optimal Dosing for Targeted Therapies in Oncology: Drug Development Cases Leading by Example</article-title><source>Clin. Cancer Res.</source><volume>22</volume><year>2016</year><fpage>1318</fpage><lpage>1324</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.ccr-15-1295</pub-id><pub-id pub-id-type="pmid">26597302</pub-id></element-citation></ref><ref id="bib39"><label>39</label><element-citation id="sref39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Levit</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Arora</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kluetz</surname><given-names>P.G.</given-names></name><name name-style="western"><surname>Magnuson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rahman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Harvey</surname><given-names>R.D.</given-names></name></person-group><article-title>Call to Action for Improving Oral Anticancer Agent Adherence</article-title><source>J. Clin. Oncol.</source><volume>40</volume><year>2022</year><fpage>1036</fpage><lpage>1040</lpage><pub-id pub-id-type="doi">10.1200/jco.21.02529</pub-id><pub-id pub-id-type="pmid">34990218</pub-id></element-citation></ref><ref id="bib40"><label>40</label><element-citation id="sref40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodney</surname><given-names>S.</given-names></name><name name-style="western"><surname>Banerji</surname><given-names>U.</given-names></name></person-group><article-title>Optimizing the FDA's Project Optimus: opportunities and challenges</article-title><source>Nat. Rev. Clin. Oncol.</source><volume>21</volume><year>2024</year><fpage>165</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1038/s41571-023-00853-z</pub-id><pub-id pub-id-type="pmid">38129533</pub-id></element-citation></ref><ref id="bib41"><label>41</label><element-citation id="sref41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gettinger</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Huber</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Bazhenova</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Tiseo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Langer</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Paz-Ares Rodríguez</surname><given-names>L.G.</given-names></name><name name-style="western"><surname>West</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Reckamp</surname><given-names>K.L.</given-names></name><etal/></person-group><article-title>Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials</article-title><source>JTO Clin. Res. Rep.</source><volume>3</volume><year>2022</year><object-id pub-id-type="publisher-id">100385</object-id><pub-id pub-id-type="doi">10.1016/j.jtocrr.2022.100385</pub-id><pub-id pub-id-type="pmcid">PMC9440305</pub-id><pub-id pub-id-type="pmid">36065449</pub-id></element-citation></ref><ref id="bib42"><label>42</label><element-citation id="sref42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moher</surname><given-names>D.</given-names></name><name name-style="western"><surname>Liberati</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tetzlaff</surname><given-names>J.</given-names></name><name name-style="western"><surname>Altman</surname><given-names>D.G.</given-names></name><collab>PRISMA Group</collab></person-group><article-title>Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement</article-title><source>PLoS Med.</source><volume>339</volume><year>2009</year><object-id pub-id-type="publisher-id">b2535</object-id><pub-id pub-id-type="doi">10.1136/bmj.b2535</pub-id><pub-id pub-id-type="pmcid">PMC3090117</pub-id><pub-id pub-id-type="pmid">21603045</pub-id></element-citation></ref><ref id="bib43"><label>43</label><element-citation id="sref43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jadad</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Moore</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Carroll</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jenkinson</surname><given-names>C.</given-names></name><name name-style="western"><surname>Reynolds</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Gavaghan</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>McQuay</surname><given-names>H.J.</given-names></name></person-group><article-title>Assessing the quality of reports of randomized clinical trials: is blinding necessary? Controlled clinical</article-title><source>Trials</source><volume>17</volume><year>1996</year><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1016/0197-2456(95)00134-4</pub-id><pub-id pub-id-type="pmid">8721797</pub-id></element-citation></ref></ref-list><sec id="appsec2" sec-type="supplementary-material"><title>Supplemental information</title><p id="p0230">
<supplementary-material content-type="local-data" id="mmc1" orientation="portrait" position="float"><caption><title>Document S1. Figure S1, Tables S1–S5, and Appendices S1–S3</title></caption><media orientation="portrait" position="float" xlink:href="mmc1.pdf" xmlns:xlink="http://www.w3.org/1999/xlink"/></supplementary-material>
</p></sec><fn-group><fn fn-type="supplementary-material" id="appsec1"><p id="p0225">Supplemental information can be found online at <ext-link ext-link-type="uri" id="intref0050" xlink:href="https://doi.org/10.1016/j.isci.2025.114613" xmlns:xlink="http://www.w3.org/1999/xlink">https://doi.org/10.1016/j.isci.2025.114613</ext-link>.</p></fn></fn-group></back></article>